Somewhat Positive Press Coverage Somewhat Unlikely to Impact BioMarin Pharmaceutical (NASDAQ:BMRN) Share Price

Media headlines about BioMarin Pharmaceutical (NASDAQ:BMRN) have trended somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioMarin Pharmaceutical earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.6988341521787 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

NASDAQ BMRN traded down $0.30 during trading on Friday, reaching $83.59. 1,396,913 shares of the company’s stock were exchanged, compared to its average volume of 1,356,805. BioMarin Pharmaceutical has a fifty-two week low of $75.81 and a fifty-two week high of $100.51. The company has a current ratio of 2.70, a quick ratio of 2.12 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $13,994.23, a PE ratio of -124.76 and a beta of 1.69.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.06). BioMarin Pharmaceutical had a negative return on equity of 3.18% and a negative net margin of 8.91%. The firm had revenue of $358.31 million for the quarter, compared to analysts’ expectations of $346.24 million. research analysts anticipate that BioMarin Pharmaceutical will post -0.16 EPS for the current year.

A number of research firms have issued reports on BMRN. Wedbush upgraded shares of BioMarin Pharmaceutical from a “neutral” rating to an “outperform” rating and set a $110.00 target price on the stock in a report on Thursday, December 14th. Goldman Sachs raised shares of BioMarin Pharmaceutical from a “buy” rating to a “conviction-buy” rating in a research report on Friday, December 15th. BidaskClub upgraded BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Saturday, December 16th. Zacks Investment Research upgraded BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $101.00 price target for the company in a report on Tuesday, January 16th. Finally, Credit Suisse Group reiterated an “outperform” rating and set a $113.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, January 18th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. BioMarin Pharmaceutical has a consensus rating of “Buy” and an average price target of $112.34.

In other news, EVP George Eric Davis sold 30,000 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $90.66, for a total transaction of $2,719,800.00. Following the sale, the executive vice president now owns 112,942 shares of the company’s stock, valued at approximately $10,239,321.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jeffrey Robert Ajer sold 1,537 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, March 29th. The stock was sold at an average price of $79.69, for a total value of $122,483.53. Following the sale, the executive vice president now directly owns 55,033 shares in the company, valued at approximately $4,385,579.77. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 85,269 shares of company stock worth $7,301,002. Company insiders own 1.85% of the company’s stock.

WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact BioMarin Pharmaceutical (NASDAQ:BMRN) Share Price” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://ledgergazette.com/2018/04/14/biomarin-pharmaceutical-bmrn-receiving-somewhat-positive-media-coverage-report-shows.html.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply